New Electronic Genome Mapping Data Shows Cancer Research
A new platform provides researchers a detailed view of genomic changes in hematologic cancers for laboratory use.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Should healthcare systems integrate new genomic mapping technologies alongside traditional diagnostic methods?
Nabsys recently presented preliminary data on its Electronic Genome Mapping technology for identifying complex genomic changes in hematologic cancers. This research, shared at a recent conference, is currently intended for laboratory use only.
Why it matters
Understanding complex genomic changes is crucial for researchers studying hematologic cancers, as these structural variations are often difficult to detect with traditional methods. New mapping platforms aim to provide a more complete view of these alterations to better support future cancer research.
Researchers shared preliminary data comparing Electronic Genome Mapping results against established cytogenetic methods for characterizing hematologic malignancies. The research remains in a preliminary stage with the OhmX Platform currently restricted to research use only.
The players
Nabsys
A biotechnology company based in Providence, RI, that develops genomic mapping technologies for research.
Columbia University Medical Center
An academic medical research institution where the OhmX Platform was installed.
Hitachi High-Tech America
A subsidiary of a global conglomerate that partners with Nabsys on the RAMP UP Program.
The details
The OhmX Platform utilizes Electronic Genome Mapping to provide a genome-wide view of structural and copy number variations. Nabsys also showcased its cloud-based Navigator platform, which features the SV-Discover and SV-Verify pipelines to analyze and visualize these findings. The technology is designed to help researchers identify complex genomic shifts that may be challenging to capture using standard cytogenetic techniques.
Timeline
October 20-24, 2026: The ASHG 2026 Annual Meeting took place in Montréal.
October 22, 2026: Nabsys presented its findings during a sponsored CoLab session.
Health Landscape
The deployment of new genomic mapping tools like the OhmX Platform reflects a broader effort to improve the detection of complex structural variations in cancer research. This development follows a pattern of integrating cloud-based analysis to refine how researchers interpret genomic data.
This development is for research use and does not currently impact clinical diagnostics or patient care decisions. Individuals interested in how genomic testing relates to hematologic malignancy management should consult with an oncologist to discuss established diagnostic pathways.
The takeaway
Advancing our ability to map complex genomic variations is a key step in better understanding the underlying causes of hematologic cancers. Researchers and patients should continue to follow official guidance on proven, clinically approved diagnostic tests for cancer care.
Further reading
For more on evolving laboratory techniques in oncology, visit our Cancer section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Should healthcare systems integrate new genomic mapping technologies alongside traditional diagnostic methods?
